MCID: MSC004
MIFTS: 39

Muscle Tissue Disease

Categories: Muscle diseases

Aliases & Classifications for Muscle Tissue Disease

MalaCards integrated aliases for Muscle Tissue Disease:

Name: Muscle Tissue Disease 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:66

Summaries for Muscle Tissue Disease

MalaCards based summary : Muscle Tissue Disease is related to localized lipodystrophy and cytoplasmic body myopathy. An important gene associated with Muscle Tissue Disease is DMD (Dystrophin), and among its related pathways/superpathways are BMP Pathway and Dilated cardiomyopathy (DCM). The drugs Lidocaine and Hyaluronic acid have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and spinal cord, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Muscle Tissue Disease

Diseases related to Muscle Tissue Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Related Disease Score Top Affiliating Genes
1 localized lipodystrophy 11.2 DMD DYSF
2 cytoplasmic body myopathy 11.1 DMD UTRN
3 juvenile spinal muscular atrophy 11.1 SMN1 SMN2
4 anterior compartment syndrome 11.1 ANO5 DYSF
5 oculopharyngodistal myopathy 11.1 GNE PABPN1
6 survival motor neuron spinal muscular atrophy 11.0 SMN1 SMN2
7 cardiomyopathy, dilated, 3b 11.0 DMD SGCA
8 charcot-marie-tooth disease, dominant intermediate b 11.0 MTM1 RYR1
9 cardiomyopathy, dilated, 1d 11.0 DAG1 DMD LAMA2
10 spinal muscular atrophy, type iv 11.0 MSTN SMN1 SMN2
11 creatine phosphokinase, elevated serum 11.0 ANO5 DMD LAMA2
12 congenital muscular dystrophy without intellectual disability 11.0 FKRP FKTN
13 spinal muscular atrophy, type iii 11.0 SMN1 SMN2
14 bethlem myopathy 1 11.0 CAPN3 DMD DYSF
15 autosomal recessive limb-girdle muscular dystrophy type 2f 11.0 CAPN3 DYSF SGCA
16 myopathy, congenital 11.0 DMD MTM1 RYR1
17 spinal muscular atrophy, type ii 11.0 SMN1 SMN2
18 centronuclear myopathy 10.9 DMD MTM1 RYR1
19 malignant hyperthermia 10.9 DMD LAMA2 RYR1
20 polyglucosan body myopathy 1 with or without immunodeficiency 10.9 CAPN3 DMD FKRP
21 spinal disease 10.9 SMN1 SMN2
22 brody myopathy 10.9 CLCN1 DMD RYR1
23 autosomal dominant limb-girdle muscular dystrophy type 1c 10.9 DYSF FKRP
24 muscular dystrophy-dystroglycanopathy , type a, 1 10.9 FKRP FKTN
25 autosomal recessive limb-girdle muscular dystrophy type 2h 10.9 CAPN3 DYSF FKRP
26 muscular dystrophy, limb-girdle, type 2h 10.9 CAPN3 DYSF FKRP
27 muscular dystrophy, limb-girdle, type 1c 10.9 DYSF FKRP MSTN
28 muscular dystrophy, limb-girdle, type 2g 10.9 CAPN3 DYSF FKRP
29 myotonia 10.9 CLCN1 DMD MSTN
30 myopathy, proximal, and ophthalmoplegia 10.9 EMD RYR1
31 rigid spine muscular dystrophy 1 10.9 DMD DYSF LAMA2 RYR1
32 cardiomyopathy, dilated, 1b 10.9 DAG1 DMD FKTN LAMA2
33 muscular dystrophy, limb-girdle, type 2j 10.9 CAPN3 FKRP
34 central core myopathy 10.9 MTM1 RYR1
35 muscular dystrophy-dystroglycanopathy , type c, 4 10.8 FKRP FKTN
36 cardiomyopathy, dilated, 1a 10.8 DAG1 DMD EMD LAMA2
37 mcleod syndrome 10.8 DMD SGCA
38 autosomal recessive limb-girdle muscular dystrophy type 2b 10.8 ANO5 CAPN3 DYSF SGCA
39 progressive muscular atrophy 10.8 SMN1 SMN2
40 congenital fiber-type disproportion 10.8 DMD DYSF EMD RYR1
41 myopathy, x-linked, with excessive autophagy 10.8 DMD EMD GNE LAMA2
42 ptosis 10.8 MTM1 PABPN1 RYR1
43 muscular dystrophy-dystroglycanopathy , type c, 5 10.8 CAPN3 DYSF FKRP LAMA2
44 dystrophinopathies 10.8 DMD UTRN
45 atrial standstill 1 10.8 DMD EMD FKRP
46 lissencephaly 10.7 DAG1 FKRP FKTN
47 familial periodic paralysis 10.7 CLCN1 RYR1
48 muscular dystrophy, limb-girdle, type 2l 10.7 ANO5 DYSF FKRP FKTN
49 muscular dystrophy, limb-girdle, type 2d 10.7 CAPN3 DYSF FKRP SGCA
50 muscular dystrophy, limb-girdle, type 2c 10.7 CAPN3 DAG1 DMD DYSF SGCA

Graphical network of the top 20 diseases related to Muscle Tissue Disease:



Diseases related to Muscle Tissue Disease

Symptoms & Phenotypes for Muscle Tissue Disease

MGI Mouse Phenotypes related to Muscle Tissue Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 EMD FKRP FKTN GNE LAMA2 MSTN
2 homeostasis/metabolism MP:0005376 10.32 ANO5 CAPN3 CLCN1 DAG1 DMD DYSF
3 cardiovascular system MP:0005385 10.23 CAPN3 DAG1 DMD FKRP GNE MSTN
4 muscle MP:0005369 10.23 PABPN1 RYR1 SGCA SMN2 UTRN ANO5
5 growth/size/body region MP:0005378 10.22 CAPN3 CLCN1 DAG1 DMD FKRP FKTN
6 cellular MP:0005384 10.21 MSTN MTM1 PABPN1 RYR1 SMN2 ANO5
7 mortality/aging MP:0010768 10.13 CLCN1 DAG1 DMD FKRP FKTN GNE
8 no phenotypic analysis MP:0003012 9.7 CLCN1 DMD DYSF MSTN MTM1 SMN2
9 reproductive system MP:0005389 9.56 ANO5 CAPN3 CLCN1 DMD LAMA2 MTM1
10 skeleton MP:0005390 9.28 CLCN1 DMD FKRP LAMA2 MSTN MTM1

Drugs & Therapeutics for Muscle Tissue Disease

Drugs for Muscle Tissue Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 766)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
2
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 9004-61-9 53477741
3
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 2216-51-5 16666
4
Simvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 79902-63-9 54454
5
Abatacept Approved Phase 4,Phase 3,Phase 2,Early Phase 1 332348-12-6 10237
6
Ramipril Approved Phase 4 87333-19-5 5362129
7
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 1 202409-33-4 123619
8
Doxycycline Approved, Investigational, Vet_approved Phase 4,Not Applicable 564-25-0 54671203
9
Dopamine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
10
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
11
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2 27203-92-5 33741
12
Cortisone acetate Approved, Investigational Phase 4,Not Applicable 1950-04-4, 50-04-4 5745
13
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
14
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
15
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60142-96-3 3446
16
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-48-6 2160
17
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1134-47-0 2284
18
Pirfenidone Approved, Investigational Phase 4 53179-13-8 40632
19
Colchicine Approved Phase 4,Phase 3,Not Applicable 64-86-8 6167 2833
20
Bezafibrate Approved, Investigational Phase 4,Phase 3,Phase 2 41859-67-0 39042
21
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 148553-50-8 5486971
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
23
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 124-94-7 31307
24
Nitroglycerin Approved, Investigational Phase 4,Phase 2,Not Applicable 55-63-0 4510
25
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
26
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 103-90-2 1983
27
Propranolol Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 525-66-6 4946
28
Citalopram Approved Phase 4,Not Applicable 59729-33-8 2771
29
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15687-27-1 3672
30
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
31
Milnacipran Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 92623-85-3 65833
32
Perphenazine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-39-9 4748
33
Azathioprine Approved Phase 4,Not Applicable 446-86-6 2265
34
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 378-44-9 9782
35
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
36
Ethanol Approved Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
37
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
38
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
39
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
40
Dinoprostone Approved Phase 4,Not Applicable 363-24-6 5280360
41
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1972-08-3 16078
42
Sodium oxybate Approved Phase 4,Phase 3,Phase 2 502-85-2 5360545
43
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 303-53-7 2895
44
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
45
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 56-12-2 119
46
Polidocanol Approved Phase 4,Phase 2 9002-92-0
47
Naproxen Approved, Vet_approved Phase 4,Not Applicable 22204-53-1 1302 156391
48
Lumiracoxib Approved, Investigational Phase 4 220991-20-8 151166
49
Mexiletine Approved, Investigational Phase 4,Phase 3,Phase 2 31828-71-4 4178
50
Sertraline Approved Phase 4 79617-96-2 68617

Interventional clinical trials:

(show top 50) (show all 2794)
# Name Status NCT ID Phase Drugs
1 Identification of Carnitine-Responsive Cardiomyopathy Unknown status NCT01904396 Phase 4 Carnitine
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
4 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
5 6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome Unknown status NCT00127985 Phase 4 6-methyl-prednisolone
6 A Randomized Trial to Evaluate the Effectiveness of Transferring the Flexor Hallucis Longus Tendon Unknown status NCT01341509 Phase 4
7 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4 Milnacipran
8 Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia Unknown status NCT00755521 Phase 4 etoricoxib
9 The Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation Unknown status NCT01825304 Phase 4
10 Ramipril Versus Carvedilol in Duchenne and Becker Patients Unknown status NCT00819845 Phase 4 carvedilol;ramipril
11 The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4 Carvedilol
12 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
13 Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity Unknown status NCT02757404 Phase 4
14 Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain Unknown status NCT02339662 Phase 4 Gabapentin;Amitriptyline
15 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
16 Corticosteroid Injection Verses High Energy Extracorporeal Shock Wave Therapy for Lateral Epicondylitis Unknown status NCT02613455 Phase 4 Kenalog (triamcinolone);lidocaine 1% (lidocaine HCl 20mg)
17 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
18 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
19 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
20 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
21 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
22 Evaluation of the Effects of L-Carnitine Injection in Patients Undergoing Hemodialysis Unknown status NCT00173706 Phase 4 L-Carnitine Injection
23 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
24 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
25 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
26 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
27 Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis Unknown status NCT01400464 Phase 4 Prednisone therapy and pharmacokinetic
28 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
29 The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM) Completed NCT01527318 Phase 4 Fibrate treatment
30 Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity Completed NCT00199745 Phase 4 atorvastatin
31 Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity Completed NCT00120055 Phase 4 Atorvastatin (Lipitor)
32 Investigations on Differences in Atorvastatin Metabolites Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity Completed NCT00414531 Phase 4 Atorvastatin
33 Using Clonidine to Improve Leg Weakness in People With Heart Failure Completed NCT00858845 Phase 4 Clonidine Patch
34 Two Different Dosages of Nebulized Steroid Versus Parenteral Steroid in the Management of COPD Exacerbations Completed NCT01865500 Phase 4 Budesonide 4 mg;Budesonide 8 mg;Metil prednisolone
35 Effects of Vitamin D Supplementation in Obesity Completed NCT01037140 Phase 4 Cholecalciferol;placebo
36 Effect of Gemfibrozil on the Safety and Pharmacokinetics of Red Yeast Rice in Healthy Subjects Completed NCT01385020 Phase 4 Gemfibrozil & red yeast rice (LipoCol)
37 Early Goal-Directed Nutrition in ICU Patients - EAT-ICU Trial Completed NCT01372176 Phase 4
38 Effect of Goserelin (Zoladex®) in Spinal and Bulbar Muscular Atrophy Completed NCT00851461 Phase 4 Goserelin
39 Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery Completed NCT00656292 Phase 4 Simvastatin;Placebo
40 Relation Between Intrabdominal Pressure and Collapsibility Index of Inferior Vena Cava Before and After Fluid Therapy Completed NCT01553422 Phase 4
41 Shockwave Therapy of Chronic Achilles Tendinopathy Completed NCT00958620 Phase 4
42 "NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes" Completed NCT00792376 Phase 4 etoricoxib;diclofenac
43 The Value of Platelet-Rich Plasma in Chronic Midportion Achilles Tendinopathy: a Double-blind Randomized Clinical Trial Completed NCT00761423 Phase 4
44 Achilles Tendinosis Study; Comparison of Radiofrequency to Surgical MicroDebridement Completed NCT00534781 Phase 4
45 The Efficacy of Polidocanol Injections as a Treatment of Chronic Achilles. Tendinopathy Completed NCT00377910 Phase 4 Aethoxysclerol
46 Colloids in Severe Trauma Completed NCT00890383 Phase 4 tetrastarch (Voluven)
47 Discomfort and Psychosocial Difficulties in Fibromyalgia Completed NCT02078791 Phase 4 Botox infiltration
48 Strengthening Exercises for Fibromyalgia Completed NCT02063750 Phase 4
49 Heart Rate Variability in Fibromyalgia - Effects of Strengthening Exercises Completed NCT02004405 Phase 4
50 Quetiapine Compared With Placebo in the Management of Fibromyalgia Completed NCT01458964 Phase 4 Quetiapine

Search NIH Clinical Center for Muscle Tissue Disease

Genetic Tests for Muscle Tissue Disease

Anatomical Context for Muscle Tissue Disease

MalaCards organs/tissues related to Muscle Tissue Disease:

41
Testes, Heart, Spinal Cord, Brain, Bone, Skeletal Muscle, Kidney

Publications for Muscle Tissue Disease

Variations for Muscle Tissue Disease

Expression for Muscle Tissue Disease

Search GEO for disease gene expression data for Muscle Tissue Disease.

Pathways for Muscle Tissue Disease

GO Terms for Muscle Tissue Disease